AstraZeneca beats sales and profit expectations on cancer drug demand
Core earnings for the three months ended March rise to US$2.58 per share, while total revenue jumps 8% to US$15.3 billion
Add BT as a preferred source
[LONDON] AstraZeneca surpassed first-quarter sales and profit expectations, and maintained its 2026 outlook on Wednesday (Apr 29).
This comes as demand for its cancer drugs and investments in key markets helped the drugmaker navigate a complex geopolitical landscape.
Long-time CEO Pascal Soriot, 66, is steering the European drugmaking giant towards its goal of US$80 billion in annual sales by 2030, expanding AstraZeneca’s US and China footprint while manoeuvring geopolitics and shifting dynamics in the industry.
The company’s core earnings for the three months ended March rose to US$2.58 per share, while its total revenue jumped 8 per cent to US$15.3 billion at constant currency rates.
Analysts on average were expecting profit of US$2.54 per share on sales of US$14.9 billion, based on a company-compiled consensus.
AstraZeneca continued to expect core earnings per share this year to increase by a low double-digit percentage at constant currencies, with total revenues rising at a mid-to-high single-digit rate. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Singapore households’ net wealth up, but also taking on more debt such as home loans
With new S$10 million HQ, Jumbo Group looks to Shanghai-focused China strategy, premium dining for growth
Up to 11 new condo projects with 3,550 units lined up for H2 launch as price ceilings emerge
Yeo’s, Tiger Beer and now Gardenia – flight of food manufacturing from Singapore might be just as planned
